J&J wants FDA to force different names on biosimilars
Johnson & Johnson has petitioned for biological drugs that are similar to the originals, but not the same, to be given drug names accordingly, asking the FDA to stop manufacturers using the same non-proprietary names.
The citizen petition (http://www.jnj.com/sites/default/files/pdf/JnJ-Petition-Biosimilars-Naming-FINAL.pdf) to the FDA, says: “Ensuring that biosimilars receive nonproprietary names that are similar to, yet distinguishable from, those of their reference products and other biosimilars is critical for patient safety. Biosimilars are, scientifically and legally, similar to but not the same as their reference products.”
Janssen Pharmaceutical companies of Johnson & Johnson submit citizen petition to the US FDA regarding naming of biosimilars (Johnson & Johnson press release).
Don't miss your daily pharmaphorum news.
SUBSCRIBE free here.